JP2011515337A5 - - Google Patents

Download PDF

Info

Publication number
JP2011515337A5
JP2011515337A5 JP2010548932A JP2010548932A JP2011515337A5 JP 2011515337 A5 JP2011515337 A5 JP 2011515337A5 JP 2010548932 A JP2010548932 A JP 2010548932A JP 2010548932 A JP2010548932 A JP 2010548932A JP 2011515337 A5 JP2011515337 A5 JP 2011515337A5
Authority
JP
Japan
Prior art keywords
group
optionally substituted
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010548932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011515337A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/035609 external-priority patent/WO2009108912A1/en
Publication of JP2011515337A publication Critical patent/JP2011515337A/ja
Publication of JP2011515337A5 publication Critical patent/JP2011515337A5/ja
Withdrawn legal-status Critical Current

Links

JP2010548932A 2008-02-29 2009-02-28 プロテインキナーゼモジュレーター Withdrawn JP2011515337A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6784508P 2008-02-29 2008-02-29
US61/067,845 2008-02-29
US10390808P 2008-10-08 2008-10-08
US61/103,908 2008-10-08
PCT/US2009/035609 WO2009108912A1 (en) 2008-02-29 2009-02-28 Protein kinase modulators

Publications (2)

Publication Number Publication Date
JP2011515337A JP2011515337A (ja) 2011-05-19
JP2011515337A5 true JP2011515337A5 (https=) 2013-05-02

Family

ID=41016490

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010548932A Withdrawn JP2011515337A (ja) 2008-02-29 2009-02-28 プロテインキナーゼモジュレーター

Country Status (8)

Country Link
US (2) US8168651B2 (https=)
EP (1) EP2259678A4 (https=)
JP (1) JP2011515337A (https=)
CN (1) CN102036561A (https=)
AU (1) AU2009219154A1 (https=)
CA (1) CA2716755A1 (https=)
MX (1) MX2010009445A (https=)
WO (1) WO2009108912A1 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0719123A2 (pt) 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
CN102015651B (zh) 2008-03-03 2014-12-31 Irm责任有限公司 作为tlr活性调节剂的化合物和组合物
US20100173013A1 (en) * 2009-01-08 2010-07-08 Denis Drygin Treatment of neoplastic disorders using combination therapies
KR20120044281A (ko) * 2009-04-17 2012-05-07 사일린 파마슈티칼스, 인크 단백질 키나제 ck2 활성과 관련된 장애의 치료 방법
US9968574B2 (en) * 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
US20110065698A1 (en) * 2009-08-26 2011-03-17 Cylene Pharmaceuticals, Inc. Novel protein kinase modulators
MX2012002480A (es) * 2009-09-03 2012-03-26 Bristol Myers Squibb Co Inhibidores de jak2 y su uso en el tratamiento de enfermedades mieloproliferativas y cancer.
BR112012005957A2 (pt) * 2009-09-16 2019-09-24 Cylene Pharmaceuticals Inc compostos tricíclicos e usos farmacêuticos dos mesmos
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
NZ599830A (en) 2009-11-05 2014-08-29 Rhizen Pharmaceuticals Sa Novel kinase modulators
US8853235B2 (en) * 2009-11-23 2014-10-07 Senhwa Biosciences, Inc. Polymorphs and salts of a kinase inhibitor
US10106798B2 (en) 2010-01-05 2018-10-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) FLT3 receptor antagonists for the treatment or the prevention of pain disorders
HUE045270T2 (hu) * 2010-01-05 2019-12-30 Inst Nat Sante Rech Med FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
TWI503323B (zh) 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之pbk抑制劑
PH12013502240B1 (en) 2011-05-04 2018-06-27 Rhizen Pharmaceuticals Sa Novel compounds as modulators of protein kinase
CN102731431A (zh) * 2012-06-20 2012-10-17 盛世泰科生物医药技术(苏州)有限公司 一种5-溴噻唑-4-甲酸的制备方法
RS56494B1 (sr) 2012-07-04 2018-01-31 Rhizen Pharmaceuticals S A Selektivni inhibitori pi3k delta
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
PE20191245A1 (es) 2013-01-15 2019-09-18 Incyte Holdings Corp Compuestos de tiazolcarboxamidas y piridinacarboxamida utiles como inhibidores de quinasa pim
CN112472699A (zh) 2013-07-26 2021-03-12 种族肿瘤学公司 改善比生群及衍生物的治疗益处的组合方法
EA201690458A1 (ru) 2013-08-23 2016-07-29 Инсайт Корпорейшн Фуро- и тиенопиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы
US9822124B2 (en) 2014-07-14 2017-11-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016196244A1 (en) 2015-05-29 2016-12-08 Incyte Corporation Pyridineamine compounds useful as pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Pim激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
CN108341774B (zh) * 2017-01-25 2022-07-19 首药控股(北京)股份有限公司 取代的喹啉酮类抑制剂
EP3706735A1 (en) 2017-11-06 2020-09-16 Snap Bio, Inc. Pim kinase inhibitor compositions, methods, and uses thereof
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
US11584763B2 (en) 2017-12-22 2023-02-21 Hibercell, Inc. Chromenopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
US11071727B2 (en) 2018-01-26 2021-07-27 Northwestern University Therapeutic targeting of proteolytic cleavage of the mixed lineage leukemia gene product (MLL1) by taspase1 using kinase inhibitors
US11332476B2 (en) * 2018-04-03 2022-05-17 3Sm Biotron Inc. Fms-like tyrosine kinase inhibitors
EA202191349A1 (ru) * 2018-11-15 2021-08-10 Ниппон Синяку Ко., Лтд. 1,3,4-оксадиазолон и фармацевтический препарат
CN109369526A (zh) * 2018-12-19 2019-02-22 桂林理工大学 一种两面针碱衍生物的合成方法及其抗肿瘤应用
GB201902759D0 (en) 2019-02-28 2019-04-17 Benevolentai Bio Ltd Compositions and uses thereof
TW202112784A (zh) 2019-06-17 2021-04-01 美商佩特拉製藥公司 作為磷脂酸肌醇磷酸激酶抑制劑之𠳭唏并嘧啶衍生物
CN111320605A (zh) * 2020-03-09 2020-06-23 吉林工程技术师范学院 一种银催化的含氟菲啶衍生物的制备方法
CN113444084A (zh) * 2020-03-26 2021-09-28 东南大学 一类抗肿瘤化合物及其制备与用途
CN113444085B (zh) * 2020-03-26 2022-04-08 东南大学 一种具有克服顺铂耐药的抗肿瘤化合物及其制备与应用
AU2021249224A1 (en) * 2020-03-30 2022-12-01 Senhwa Biosciences, Inc. Antiviral compounds and method for treating hepatotropic viral infection, particularly hepatitis B and hepatitis D
EP3967307A1 (en) 2020-09-15 2022-03-16 Instytut Hematologii I Transfuzologii Use of pim kinase inhibitors to augment the efficacy of anti-cd20 antibody-based therapies in hematologic malignancies and non-malignant conditions
AU2021360636A1 (en) * 2020-10-16 2023-06-15 Shanghai De Novo Pharmatech Co., Ltd. Triheterocyclic derivative, and pharmaceutical composition and application thereof
GB202102895D0 (en) * 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2023126951A1 (en) * 2022-01-03 2023-07-06 Yeda Research And Development Co. Ltd. Inhibitors of autophagy-related protein-protein interactions
WO2023225586A2 (en) * 2022-05-19 2023-11-23 4M Therapeutics Inc. Novel azaphenantrhene derivatives as inhibitors of glycogen synthase kinase 3 for therapeutic use
KR20250140599A (ko) * 2023-02-03 2025-09-25 미라티 테라퓨틱스, 인크. 치환된 트리시클릭 화합물
US11987581B1 (en) 2023-12-19 2024-05-21 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-2-carboxylic acids as CK2 inhibitors
US12024518B1 (en) 2023-12-20 2024-07-02 King Faisal University Pyrazolo[4,3-C][1,6]naphthyridines as CK2 inhibitors
US12012414B1 (en) 2024-01-04 2024-06-18 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrimidines as CK2 inhibitors
US11964974B1 (en) 2024-01-08 2024-04-23 King Faisal University Imidazo[1,2-c]pyrido[3,4-e]pyrimidine-3-carboxylic acids as CK2 inhibitors
US11981676B1 (en) 2024-01-16 2024-05-14 King Faisal University Pyrazolo[4,3-c][2,6]naphthyridines as CK2 inhibitors
US12187726B1 (en) 2024-02-06 2025-01-07 King Faisal University Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991064A (en) * 1975-01-17 1976-11-09 Warner-Lambert Company Benzonaphthyridines
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
MY148521A (en) 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
WO2007007152A2 (en) 2005-07-11 2007-01-18 Pfizer Limited Anti-madcam antibodies to treat metastatic cancers and chloroma
US7589101B2 (en) * 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
JP2009519336A (ja) * 2005-12-13 2009-05-14 ワイス ジベンゾナフチリジン誘導体およびそれらの使用方法
BRPI0719123A2 (pt) * 2006-09-01 2013-12-17 Cylene Pharmaceuticals Inc Moduladores de serina-treonina proteína cinase e parp
WO2008042282A2 (en) 2006-09-28 2008-04-10 Exelixis, Inc. Imidazole-4, 5-dicarboxamide derivatives as jak-2 modulators
WO2008109613A1 (en) * 2007-03-05 2008-09-12 Wyeth Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2011515337A5 (https=)
JP5976778B2 (ja) キナーゼ阻害剤としてのピラゾリル−ピリミジン誘導体
EP2699564B1 (en) Substituted pyrimidinyl-pyrroles active as kinase inhibitors
RU2011124304A (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP6215832B2 (ja) アミノピリミジンキナーゼ阻害剤
EP3196197A1 (en) Indoleamine-2,3-dioxygenase inhibitor and preparation method therefor
JP2019527725A (ja) 4位置換アミノイソキノリン誘導体
JP2010529140A (ja) サイクリン依存性キナーゼの選択的阻害剤
TW201808888A (zh) 整合應激途徑之調節劑
KR20180017013A (ko) K-Ras 조절제
JP2019077713A5 (https=)
EP3154957A1 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2012520288A (ja) ピラゾロ[1,5−a]−1,3,5−トリアジン誘導体、その調製、及びその治療的使用方法
JP2013538213A5 (https=)
RU2013112871A (ru) Соединения для лечения рака
CN108794453A (zh) 一种靶向降解fak蛋白的化合物及其应用
EP3699179A1 (en) Pyrazolyl-containing tricyclic derivative, preparation method therefor and use thereof
JP2020509997A5 (https=)
JP6542236B2 (ja) 有機化合物
RU2011136855A (ru) Производные бензотиазолов и бензимидазолов, содержащие 6-nh-замещенные триазолопиридазинсульфанил в положении 6: получение, применение в качестве лекарственных средств и применение в качестве ингибиторов мет
CN111039941B (zh) 一种含氮杂环化合物、其制备方法及应用
JP2018058863A (ja) キナーゼ阻害活性を有するトリプトリン誘導体及びその使用
CN115697331A (zh) Taspase1抑制剂及其用途
WO2020006724A1 (zh) 一种靶向降解fak蛋白的化合物及其应用